Basit öğe kaydını göster

dc.contributor.authorKırbaş, Serkan
dc.contributor.authorKırbaş, Aynur
dc.contributor.authorTufekçi, Ahmet
dc.contributor.authorCüre, Medine Cumhur
dc.contributor.authorÇakmak, Sevim
dc.contributor.authorYazıcı, Tarkan
dc.contributor.authorCüre, Erkan
dc.date.accessioned2020-12-19T19:56:04Z
dc.date.available2020-12-19T19:56:04Z
dc.date.issued2016
dc.identifier.citationKirbas, S., Kirbas, A., Tufekci, A., Cumhur Cure, M., Cakmak, S., Yazici, T., & Cure, E. (2016). Serum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson's disease. Acta clinica Belgica, 71(2), 71–75. https://doi.org/10.1080/17843286.2016.1138592en_US
dc.identifier.issn1784-3286
dc.identifier.issn2295-3337
dc.identifier.urihttps://doi.org/10.1080/17843286.2016.1138592
dc.identifier.urihttps://hdl.handle.net/11436/2665
dc.descriptioncure, erkan/0000-0001-7807-135X; Cure, Medine Cumhur/0000-0001-9253-6459en_US
dc.descriptionWOS: 000377621200002en_US
dc.descriptionPubMed: 27075796en_US
dc.description.abstractObjectives: Endothelial dysfunction has been implicated as a crucial event in the development of several neurodegenerative diseases. the aim of this study was to investigate the serum homocysteine, asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels in patients with Parkinson's disease (PD) and to compare the results with data from healthy controls. Methods: A total of 132 subjects, including 82 idiopathic PD patients who were newly diagnosed and untreated (47 males, 35 females, mean age of 60.8 +/- 7.1 years) and 50 healthy controls (28 males, 22 females, mean age of 60.2 +/- 6.7 years) were enrolled in this study. the serum ADMA and NO levels were determined using enzymelinked immunosorbent assay (ELISA), while the homocysteine levels were determined by chemiluminescent microparticle immunoassay. Results: the ADMA and NO levels of the PD patients were significantly higher than those of the healthy controls. the serum ADMA levels were 0.70 +/- 0.15 mu mol/L in the PD patients and 0.50 +/- 0.12 mu mol/L in the healthy controls (p < 0.001). the serum NO levels were 78.7 +/- 10.3 mu mol/L in the PD patients and 59.9 +/- 9.5 mu mol/L in the healthy controls (p < 0.001). in addition, the ADMA and NO levels were significantly correlated with the serum homocysteine levels in patients with PD (r = 0.874, p < 0.001, r = 0.803, p = 0.005, respectively). Conclusion: in our study, the high ADMA and NO levels of patients with PD indicate endothelial dysfunction, and this dysfunction may play a role in PD pathogenesis. Larger studies, including randomised clinical trials in humans and animal studies, are needed to validate our findings and help in developing a better understanding of the pathogenesis of PD.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsymmetric dimethylarginineen_US
dc.subjectNitric oxideen_US
dc.subjectHomocysteineen_US
dc.subjectParkinson's diseaseen_US
dc.titleSerum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson's diseaseen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorKırbaş, Serkan
dc.contributor.institutionauthorKırbaş, Aynur
dc.contributor.institutionauthorTufekçi, Ahmet
dc.contributor.institutionauthorCüre, Medine Cumhur
dc.contributor.institutionauthorÇakmak, Sevim
dc.contributor.institutionauthorYazıcı, Tarkan
dc.contributor.institutionauthorCüre, Erkan
dc.identifier.doi10.1080/17843286.2016.1138592
dc.identifier.volume71en_US
dc.identifier.issue2en_US
dc.identifier.startpage71en_US
dc.identifier.endpage75en_US
dc.relation.journalActa Clinica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster